# 510(k) Summary

In accordance with the requirements of 21 CFR.807.92, the following information about 510(k) safety and effectiveness is being submitted.

# 1. Submitter

CERAGEM Medisys Inc.   
#103-703, SK Ventium, 522 Dangjeong-dong,   
Gunpo-si, Gyeonggi-do, 435-776, Republic of Korea Phone : $( + 8 2 )$ 070-4172-6805   
Fax : (+82) 31-455-8822

Date Prepared

August 24, 2012

Device Name

Common name : LabonaCheck TM Alc Classification : Class II (Regulation: 21 CFR 864.7470 ) Product Code : LCP (Assay, Glycosylated Hemoglobin)

# 4Predicate Device

The LabonaCheck™M Alc is substantially equivalent to NycoCard® HbAlc described as below.

(1) Trade Name: NycoCard® HbA1c Glycated Hemoglobin Assay   
Applicant: Primus Corporation   
510(K) Number: K993131   
Regulatory Class: II   
(5.)-Product.Code:LCP

5Device Description

The systeim consists of HbAIc Analyzer (MH 200) and HbA1c Test kit. The LabonaCheck™M Alc HbAlc Analyzer measures the coloured responses of the LabonaCheckTM A1c HbA1c Test Kit by spectral reflectance.

Intended Use

Intended use(s): See indications for use. Indication(s) for use

The LabonaCheckTM Alc consists of LabonaCheckTM AIc HbAlc analyzer and LabonaCheck™m Alc HbA1c Test kit, is for in-vitro diagnostic use only. LabonaCheck TMAlc HbAlc Analyzer is designed to analyze the LabonaCheck™M Alc HbAlc Test Kit.

The LabonaCheck™m Alc is intended for the quantitative measurement of glycated hemoglobin in venous whole blood and capillary fingerstick samples. This device is intended for multiple patient, professional use. Measurement of percent glycated hemoglobin (HbA1c) is effective in monitoring long-term glucose control in individuals with diabetes mellitus by using the LabonaCheckTm Alc. Only auto-disabling, single use lancing devices should be used with this system.

# 7Comparison to Predicate Device

<table><tr><td colspan="3" rowspan="1">Comparison</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">LabonaCheck™ Alc</td><td colspan="1" rowspan="1">NycoCard@ HbAlc</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The LabonaCheck Alc is an in-vitro diagnostic test forquantitative measurement ofglycated hemoglobin (HbAlc)in venous whole blood andcapillary fingerstick samples.</td><td colspan="1" rowspan="1">The NycoCard HbAlc is arapid in vitro test formeasurement of glycatedhemoglobin in human blood.</td></tr><tr><td colspan="1" rowspan="1"></td><td></td><td colspan="1" rowspan="2">Boronate affinity assay</td></tr><tr><td colspan="1" rowspan="1">Detection Method</td><td colspan="1" rowspan="1">Boronate affinity assay</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Glycated hemoglobin (HbA1c)</td><td colspan="1" rowspan="1">Glycated hemoglobin (HbA1c)</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">5 uL</td><td colspan="1" rowspan="1">5 uL</td></tr><tr><td colspan="1" rowspan="1">Test Time</td><td colspan="1" rowspan="1">'      3 minutes</td><td colspan="1" rowspan="1">3 minutes</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">4~15%</td><td colspan="1" rowspan="1">4 ~15%</td></tr><tr><td colspan="1" rowspan="1">Storage Condition(Humidity range)(Test kit)</td><td colspan="1" rowspan="1">2~8°C, (20~70% R.H)</td><td colspan="1" rowspan="1">2~8°C(Below 70%)</td></tr><tr><td colspan="1" rowspan="1">Warranty(Analyzer)</td><td colspan="1" rowspan="1">1 year</td><td colspan="1" rowspan="1">1 year</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Power (Battery)</td><td colspan="1" rowspan="1">CR2032</td><td colspan="1" rowspan="1">NiMH</td></tr><tr><td colspan="1" rowspan="1">Storage Condition(Humidity range)</td><td colspan="1" rowspan="1">HbA1c Analyzer 10~60(15~75% R.H)</td><td colspan="1" rowspan="1">Reader II 2~25(20~70% R.H)</td></tr></table>

# Conclusion

As the comparison table, the LabonaCheck™m Alc has same intended use, detection method, analytes, same volume, test time, measuring range, storage condition , humidity range (test kit), warranty (analyzer).

To sum up with the similarities, the LabonaCheck™m Alc is similar with the predicate device because most of the specifications deciding the characteristic of the device same.

In conclusion, despite of the difference such as power (battery) and etc., the LabonaCheck™ Alc is substantially equivalent to NycoCard® HbA1c.

8. Performance characteristics

A. Analytical Performance

a.Precision/Reproducibility

Precision studies were conducted internally by the manufacturer and externally at three POC sites.Precision.studies_were.modeled from the NCCLS_guideline EP5-A2.

Internal study performed at CERAGEM Medisys Inc. Within-run, day to day and total precision were determined for whole blood samples. Test samples were analyzed per day of each sample using two meter and reagents of two lots.

Within-run, day to day and total precision, expressed as Coefficient of Variation (CV) and standard deviation (STD).

<table><tr><td rowspan=2 colspan=1>Interval</td><td rowspan=2 colspan=1>IntervalReference Alc (%)</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within run</td><td rowspan=1 colspan=2>Day to day run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>STD</td><td rowspan=1 colspan=1>C.V(%)</td><td rowspan=1 colspan=1>STD</td><td rowspan=1 colspan=1>C.V(%)</td><td rowspan=1 colspan=1>STD</td><td rowspan=1 colspan=1>C.V(%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.6</td></tr></table>

# External study

An external precision study was performed in three point-of-care sites with six operators (two at each site). Three intervals of HbAIc EDTA blood were analyzed. The results obtained on the A1c for site 1,2,3 are shown in the table below.

<table><tr><td colspan="1" rowspan="2">Interval</td><td colspan="1" rowspan="2"></td><td colspan="2" rowspan="1">POC Site 1</td><td colspan="2" rowspan="1">POC Site 1</td><td colspan="2" rowspan="1">POC Site2</td><td colspan="2" rowspan="1">POC Site2</td><td colspan="2" rowspan="1">POC Site3</td><td colspan="2" rowspan="1">POC Site3</td></tr><tr><td colspan="1" rowspan="1">OP1</td><td colspan="1" rowspan="1">OP2</td><td colspan="1" rowspan="1">OP5</td><td colspan="1" rowspan="1">OP6</td><td colspan="1" rowspan="1">OP3</td><td colspan="1" rowspan="1">OP4</td><td colspan="1" rowspan="1">OP1</td><td colspan="1" rowspan="1">OP2</td><td colspan="1" rowspan="1">OPS</td><td colspan="1" rowspan="1">OP6</td><td colspan="1" rowspan="1">OP3</td><td colspan="1" rowspan="1">OP4</td></tr><tr><td colspan="1" rowspan="9">I</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.9</td><td colspan="1" rowspan="1">4.9</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">0.15</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">3.31</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">3.1</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="2" rowspan="1">4.8</td><td colspan="2" rowspan="1">4.9</td><td colspan="2" rowspan="1">4.9</td><td colspan="2" rowspan="1">4.9</td><td colspan="2" rowspan="1">4.9</td><td colspan="2" rowspan="1">4.9</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="2" rowspan="1">0.15</td><td colspan="2" rowspan="1">0.16</td><td colspan="2" rowspan="1">0.17</td><td colspan="2" rowspan="1">0.15</td><td colspan="2" rowspan="1">0.16</td><td colspan="2" rowspan="1">0.16</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="2" rowspan="1">3.0</td><td colspan="2" rowspan="1">3.2</td><td colspan="2" rowspan="1">3.4</td><td colspan="2" rowspan="1">3.1</td><td colspan="2" rowspan="1">3.2</td><td colspan="2" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1">4.8</td><td colspan="4" rowspan="1">4.9</td><td colspan="4" rowspan="1">4.9</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="4" rowspan="1">0.16</td><td colspan="4" rowspan="1">0.16</td><td colspan="4" rowspan="1">0.16</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="4" rowspan="1">3.2</td><td colspan="4" rowspan="1">3.4</td><td colspan="4" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="2"></td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">8.7</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.6</td><td colspan="1" rowspan="1">8.8</td><td colspan="1" rowspan="1">8.8</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">0.32</td><td colspan="1" rowspan="1">0.28</td></tr><tr><td colspan="1" rowspan="4">2</td><td colspan="1" rowspan="1">C.V (%)</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">3.1</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="2" rowspan="1">8.8</td><td colspan="2" rowspan="1">8.8</td><td colspan="2" rowspan="1">8.9</td><td colspan="2" rowspan="1">8.8</td><td colspan="2" rowspan="1">8.7</td><td colspan="2" rowspan="1">8.8</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="2" rowspan="1">0.28</td><td colspan="2" rowspan="1">0.29</td><td colspan="2" rowspan="1">0.29</td><td colspan="2" rowspan="1">0.25</td><td colspan="2" rowspan="1">0.28</td><td colspan="2" rowspan="1">0.30</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="2" rowspan="1">3.2</td><td colspan="2" rowspan="1">3.2</td><td colspan="2" rowspan="1">3.2</td><td colspan="2" rowspan="1">2.8</td><td colspan="2" rowspan="1">3.2</td><td colspan="2" rowspan="1">3.4</td></tr><tr><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="1">Mean</td><td colspan="4" rowspan="1">8.8</td><td colspan="4" rowspan="1">8.8</td><td colspan="4" rowspan="1">8.7</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="4" rowspan="1">0.28</td><td colspan="4" rowspan="1">0.27</td><td colspan="4" rowspan="1">0.29</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="4" rowspan="1">3.2</td><td colspan="4" rowspan="1">3.0</td><td colspan="4" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="9">3</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">13.1</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">13.2</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">13.2</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">0.43</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">0.36</td><td colspan="1" rowspan="1">0.43</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">0.41</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">0.46</td><td colspan="1" rowspan="1">0.45</td><td colspan="1" rowspan="1">0.44</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">3.4</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="2" rowspan="1">13.2</td><td colspan="2" rowspan="1">13.2</td><td colspan="2" rowspan="1">13.2</td><td colspan="2" rowspan="1">13.2</td><td colspan="2" rowspan="1">13.3</td><td colspan="2" rowspan="1">13.3</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="2" rowspan="1">0.44</td><td colspan="2" rowspan="1">0.44</td><td colspan="2" rowspan="1">0.41</td><td colspan="2" rowspan="1">0.41</td><td colspan="2" rowspan="1">0.47</td><td colspan="2" rowspan="1">0.46</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="2" rowspan="1">3.3</td><td colspan="2" rowspan="1">3.3</td><td colspan="2" rowspan="1">3.1</td><td colspan="2" rowspan="1">3.1</td><td colspan="2" rowspan="1">3.5</td><td colspan="2" rowspan="1">3.4</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="4" rowspan="1">13.2</td><td colspan="4" rowspan="1">13.2</td><td colspan="4" rowspan="1">13.3</td></tr><tr><td colspan="1" rowspan="1">STD</td><td colspan="4" rowspan="1">0.43</td><td colspan="4" rowspan="1">0.41</td><td colspan="4" rowspan="1">0.46</td></tr><tr><td colspan="1" rowspan="1">C.V (%)</td><td colspan="4" rowspan="1">3.3</td><td colspan="4" rowspan="1">3.1</td><td colspan="4" rowspan="1">3.5</td></tr></table>

# b. Linearity/Assay Measuring Range

A linearity study across the entire clamed measuring range (4\~15%) was evaluated using low (3.2% HbA1c) and high (17.5% HbA1c) control solutions. The low and high control solutions were mixed together in ratios to make five intermediate levels. The control solutions were mixed well and divided into two aliquots. One aliquot was used to perform on the LabonaCheck™m Alc analyzer and the second aliquot was analyzed on the reference HbA1c analyzer. Real value was compared to the theoretical values based upon the dilution factor. The % recovery was calculated with the following formula: Recovery = Real value / Expected % x 100. The percent recovery between the real values verses the expected values are shown in the table below :

<table><tr><td colspan="1" rowspan="1">SampleNo.</td><td colspan="1" rowspan="1">Expected (%)</td><td colspan="1" rowspan="1">Real Value (%)</td><td colspan="1" rowspan="1">Difference (%)</td><td colspan="1" rowspan="1">% Recovery</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">108</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">5.6</td><td colspan="1" rowspan="1">5.8</td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1">103</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">8.0</td><td colspan="1" rowspan="1">8.1</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">101</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">10.4</td><td colspan="1" rowspan="1">10.5</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">101</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">12.7</td><td colspan="1" rowspan="1">12.9</td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1">102</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">15.1</td><td colspan="1" rowspan="1">15.4</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">102</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">17.5</td><td colspan="1" rowspan="1">17.5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">100</td></tr></table>

The results of the study support the sponsor's claimed that LabonaCheck™m Alc is linear from $4 \%$ to $1 5 \%$ .

# c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The LabonaCheck™ Alc device has been certified by the National Glycohemoglobin Standardization Program (NGSP). NGSP certifications are renewed annually. Current NGSP certifications are found on the web at http://www.ngsp.org/prog/index.html

# d. Detection Limit

The limit of Blank (LoB) and Limit of Detection (LoD) were determined by assaying a zero sample (blank) and five low HbAlc samples according to CLSI guideline EP17-A. A zero sample was Negative or very low concentration sample that is commutable with patient specimen. Each sample was assayed twice a day in replicates of ten (n=60) for three days on the LabonaCheck™m A1c.The detection limits were summarized in the table below :

(N{=60, $\scriptstyle N s = 6 0 )$   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Blank(%)</td><td rowspan=1 colspan=1>Low concentration (%)</td></tr><tr><td rowspan=1 colspan=1>Mean %</td><td rowspan=1 colspan=1>3.10</td><td rowspan=1 colspan=1>4.12</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.080</td><td rowspan=1 colspan=1>0.092</td></tr></table>

This assay has reportable range of $4 \%$ to $1 5 \%$ Alc.

# e. Analytical Specificity

Interference Study: Interference testing was performed using a protocol based on NCCLS EP7-A. Studies were performed to assess common or known substances that could interfere with the LabonaCheck™m Alc. The interfering substances were evaluated in Interval 1 (4.6\~6.6), Interval 2 (7.6\~9.6), and Interval 3 (9.8\~12.8). Three intervals of whole blood sample pools were spiked with interfering substance. The sponsor states that recovery within 10% of the control results was considered to be non-significant. The following compounds, at the levels indicated, were shown to have no significant interference on the LabonaCheck™M A1c test results : Ascorbic acid: 6mg/dL, Bilirubin (Conjugated): 5mg/dL, Bilirubin (Unconjugated): 5mg/dL, Glucose: 1200mg/dL, Hemoglobin: 20g/dL, Lipid (Triglyceride): 500mg/dL, Albumin: 5g/dL, K3EDTA: 300 mg/dL, Heparin: 8000 U/dL, Sodium fluoride: 1000 mg/dL, Sodium citrate: 3.20%, Acetaminophen: 30 mg/dL, Metformin: 4 mg/dL, Acetylsalicylic acid: 1000mg/dL, Glybenclamide: 5 mg/dL, Ibuprofen: $4 0 \mathrm { m g / d L }$ .

To evaluate the effect of Hemoglobin variants (F), Sponsor performed the testing using samples (HbF: 22.3\~27.8%) provided by the NGSP. When sponsor compared between test result of candidate device and result of reference device, the average bias caused by the hemoglobin F sample were within ± 10% up to 22.7%. Therefore, sponsor claimed the test results of candidate device is affected by blood sample containing HbF $( > 2 0 \% )$ .

To evaluate the effect of Hemoglobin variants (C, D, E, and S), Sponsor performed the testing using samples provided by the NGSP known to contain variants C, D, E, and, S on the LabonaCheck™ A1c. The results of LabonaCheck™M A1c were compared to NGSP's data (results of Primus). The sponsor's acceptance criteria was within ±10% of reference difference to be considered as no significant interference. Interference testing about Hemoglobin C, D, E, and S satisfied acceptance criteria.

NGSP has hemoglobin variants interference information for method at http://www.ngsp.org/prog/index.html

To evaluate the effect of Carbamylated hemoglobin and Rheumatoid factor, Sponsor performed the testing using 10 samples on the LabonaCheck™M Alc and reference device (Tosoh G7). The sponsor's acceptance criteria was within $\pm 1 0 \%$ of reference difference to be considered as no significant interference. Interference testing about Carbamylated hemoglobin and Rheumatoid factor satisfied acceptance criteria.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Carbamylated hemoglobin</td><td rowspan=1 colspan=1>Rheumatiod factor</td></tr><tr><td rowspan=1 colspan=1>Control sample</td><td rowspan=1 colspan=1>Whole blood sample</td><td rowspan=1 colspan=1>Whole blood sample</td></tr><tr><td rowspan=1 colspan=1>Test sample 1(Low)</td><td rowspan=1 colspan=1>Whole blood sample +2.5 mmol/L of sodium cyanate</td><td rowspan=1 colspan=1>Whole blood sample +100 IU/mL of rheumatoid factor</td></tr><tr><td rowspan=1 colspan=1>Test sample 2(High)</td><td rowspan=1 colspan=1>Whole blood sample +5 mmol/L of sodium cyanate</td><td rowspan=1 colspan=1>Whole blood sample +300 IU/mL. of rheumatoid factor</td></tr></table>

Hemoglobin Study: The hemoglobin study was performed with 50 whole blood samples. We selected samples ranged from 4.6 to $2 2 g / \mathrm { d L }$ over a wide range of HbAlc concentrations. According to the results, LabonaCheckTM A1c satisfied the acceptance criteria (within $10 \%$ difference) at hemoglobin concentrations ranged from $8 . 7 \mathrm { g } / \mathrm { d L }$ to $2 1 . 0 { \dot { \bf g } } / { \dot { \bf d } } { \dot { \bf L } }$ . Sponsor claimed that the hemoglobin range for HbA 1c measurement of the LabonaCheckTMAlc is $1 0 . 0 \mathrm { g } / \mathrm { d L } -$ EY $2 0 . 0 { \mathfrak { g } } / { \mathfrak { d } } \mathrm { L }$ . Lower than $1 0 . 0 { \bf g } / { \bf d } { \bf L }$ or higher than $2 0 . 0 { \dot { \bf g } } / { \bf d L }$ of hemoglobin concentration will lead to inaccurate result.

![](images/af2aa364b88c219cae6f73c9e023f234c6238ac44212ede97044d812c0126c4f.jpg)

Incubation time study: The purpose of this testing is to evaluate incubation time between HbAlc in whole blood and RI reagent have an effect on the LabonaCheck™M Alc. Each meter were performed 3 measurements using whole blood samples of 3 HbAlc concentrations (Low, Medium, High) for incubation times. According to test result, when Rl reagent and the whole blood sample incubated for 2 to 3 minutes, reference difference was within 5%. Incubated samples for 2 minutes to 3minutes were satisfied acceptance criteria.

# f. Assay cut-off

Not applicable.

B. Comparison studies

# a. Method comparison with predicate device

Accuracy: A method comparison study was performed with performed with 50 EDTA venous whole blood patient samples in two point of care sites (two at each site). The testing was performed by comparing the venous whole blood results of 50 samples (25 at each site) that spanned the claimed assay range to the results obtained by the predicate device, NycoCard®HbA1c. Samples ranged from 4.2-14.5 as measured by the reference device. The difference $\%$ are as follows:

<table><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Difference betweenLabonaCheck™A1c andTosoh G7</td><td rowspan=1 colspan=1>Difference betweenNycoCard and Tosoh G7</td><td rowspan=1 colspan=1>Difference betweenLabonaCheck™Alc andNycoCard</td></tr><tr><td rowspan=1 colspan=1>within± 10%</td><td rowspan=1 colspan=1>100%(50/50)</td><td rowspan=1 colspan=1>96%(48/50)</td><td rowspan=1 colspan=1>96%(48/50)</td></tr></table>

The.linear-regression.and.correlation.coefficient.are.asfollow:

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">Intercept</td><td colspan="1" rowspan="1">Correlation coefficient</td></tr><tr><td colspan="1" rowspan="1">LabonaCheck vsTosoh G7</td><td colspan="1" rowspan="1">1.0552</td><td colspan="1" rowspan="1">-0.4360</td><td colspan="1" rowspan="1">0.9708</td></tr><tr><td colspan="1" rowspan="1">NycoCard vs Tosoh G7</td><td colspan="1" rowspan="1">1.0613</td><td colspan="1" rowspan="1">-0.3304</td><td colspan="1" rowspan="1">0.9695</td></tr><tr><td>LabonaCheck vs NycoCard</td><td>0.9873</td><td>-0.0516</td><td>0.9873</td></tr></table>

# Point-of-Care study

Accuracy (using venous blood samples): POC study was performed with 120 EDTA venous whole blood samples in three point of care sites by 6 intended users (two at each site) on one meters. Total of 120 measurements are obtained (40 results of testing at each site) samples ranged from 4.5-14.6 as measured by the reference device. The linear regressions are as follows:

<table><tr><td></td><td>Slope (95% confidence interval)</td><td>Intercept</td><td>Correlation coefficient</td></tr><tr><td>Site 1</td><td>1.0225 (0.9850~1.0600)</td><td>-0.2129 (-0.5291~0.1034)</td><td>0.9877</td></tr><tr><td>Site 2</td><td>0.9868 (0.9466~1.0271)</td><td>0.0516 (-0.2768~0.3801)</td><td>0.9848</td></tr><tr><td>Site 3</td><td>0.9915 (0.9565~1.0265)</td><td>0.0756 (-0.2172~0.3683)</td><td>0.9886</td></tr><tr><td>All site Site 1+2+3 combined</td><td>1.0005 (0.9796~1.0215)</td><td>-0.0292 (-0.2036~0.1451)</td><td>0.9870</td></tr></table>

Accuracy (using capillary blood samples): POC study was performed with 120 capillary blood samples in three point of care sites on two meters. Total of 120 measurements are obtained (40 result of testing at each site) samples ranged from 4.2 %to $1 4 . 8 \%$ as measured by the reference device. The linear regressions are as follows:

<table><tr><td></td><td>Slope</td><td>Intercept</td><td>Correlation coefficient</td></tr><tr><td></td><td colspan="3">(95% confidence interval)</td></tr><tr><td>Site I</td><td>1.0020 (0.9629~1.0411)</td><td>0.1670 (-0.4805~0.1465)</td><td>0.9861</td></tr><tr><td>Site 2</td><td colspan="3">0.9576 (0.9185~0.9967) (0.1959~0.8280)</td></tr><tr><td>Site 3</td><td>0.9524 (0.9180~0.9869)</td><td>0.5584 (0.2773~0.8396)</td><td>0.9880</td></tr><tr><td>All site Site 1+2+3 combined</td><td>0.9692 (0.9481~0.9903)</td><td>0.4230 (0.2523~0.5937)</td><td>0.9859</td></tr></table>

According to the above results, the slope (0.9-1.1), intercept (less than $1 \%$ ), correlation coefficient results of three POC sites satisfied the acceptance criteria.

# c. Matrix comparison

Venous whole blood samples ( $\mathbf { K _ { 3 } E D T A }$ , Sodium heparin, NaF) collected from 40 donors were assayed on the LabonaCheckT Alc and compared to the reference device (Tosoh G7). Samples ranged from $4 . 5 { - } 1 4 . 1 \%$ . The results of the studies are presented below:

(1) Linear regression analysis

<table><tr><td colspan="2"></td><td rowspan="2">Intercept</td><td rowspan="2">Correlation coefficient</td></tr><tr><td></td><td>Slope (95% confidence interval)</td></tr><tr><td rowspan="2"></td><td>0.9661 Result 1</td><td>0.2442</td><td>0.9685</td></tr><tr><td>(0.9088~1.0234)</td><td>(-0.2949~0.7833)</td><td></td></tr><tr><td>KJEDTA VS</td><td>Result 2</td><td>0.9721 0.3790</td><td>0.9681</td></tr><tr><td>Sodium Heparin</td><td>(0.9140~1.0301) 0.9682</td><td>(-0.1587~0.9166) 0.3190</td><td></td></tr><tr><td rowspan="2"></td><td>Result 1+2 (0.9279~1.0085)</td><td>·(-0.0570~0.6951)</td><td>0.9670</td></tr><tr><td>0.9486</td><td>0.3807 .</td><td>0.9579</td></tr><tr><td>K3EDTA</td><td>Result 1</td><td>(0.8834~1.0139) (-0.2332~0.9946)</td><td></td></tr><tr><td>vs</td><td>..0.9498 Result 2</td><td>-0.4832</td><td>0.9567</td></tr><tr><td>NaF</td><td></td><td>(0.8834~1.0162) (-0.1318~1.0983)</td><td></td></tr><tr><td></td><td>0.9487</td><td>0.4364</td><td></td></tr><tr><td></td><td>Result 1+2 (0.9033~0.9941)</td><td>(0.0127~0.8602)</td><td>0.9569</td></tr></table>

Alc: The sponsor concluded that the foilowing anticoagulants can be used with their Alc device: $\mathbf { K _ { 3 } E D T A }$ , Sodium heparin, NaF.

# C. Safety and Reliability

Equipment temperature exposure limits: Repeatability precision using three levels of control solutions was evaluated before and after challenge with temperature change. The testing degrees of high temperature limits were 30±2c, and testing degrees of low temperature limits were $4 \pm 2 \circ c .$

There is no significant difference or tendency between the each test result measured on the each condition, $\pmb { 4 } \textcircled { \tau }$ and $3 0 \%$ , on LabonaCheck™ Alc.

Equipment Humidity exposure limits: The humidity test was evaluated using three levels of control solutions. The testing degrees of high humidity were 80%RH±5 %, and the testing degrees of normal humidity limits were 40%RH±5 %, and the testing degrees of low humidity were 10%RH±5 %. There is no significant difference·or tendency on the each test result at 10%RH, $4 0 \% \mathbb { R H }$ ,and $8 0 \% \mathbb { R } \mathbb { H }$ .

# D. Clinical studies

(1) Clinical sensitivity Not Applicable   
(2) Clinical specificity: Not Applicable   
(3) Other clinical supportable data(when a and b are not applicable) Not Applicable

# E-Clinical-cut-off:

Not Applicable

# F. Appendix

CERAGEM International c/o Raymond Chung 3699 Wilshire Blvd., Suite 930 Los Angeles, CA 90010

Re: k111128 Trade Name: LabonaCheck™M Alc Regulation Number: 21 CFR $\ S 8 6 4 . 7 4 7 0$ Regulation Name: Quantitative, Hemoglobin Alc Test System Regulatory Class: Class II Product Codes: LCP Dated: September 4, 2012 Received: September 10, 2012

Dear Raymond Chung:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and góod manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

2

Couptney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

10(k) Number (known):

Device Name: LabonaCheck" Alc

Indication For Use:

The LabonaCheck™M A1c is intended for the quantitative measurement of glycated hemoglobin in venous whole blood and capillary fingerstick samples. This device is intended for multiple patient, professional use. Measurement of percent glycated hemoglobin (HbAlc) is effective in monitoring long-term glucose control in individuals with diabetes mellitus by using the LabonaCheck™M A1c. Only auto-disabling, single use lancing devices should be used with this system.

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/a003dcd37c801cc8743f49dd1a7f9b3f77a4166533b3c374bd86dc9fd0d3427c.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) k 112.8